Best Options Strategy for CRNX
Looking for the best options strategy for Crinetics Pharmaceuticals, Inc. (CRNX)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live CRNX option chain right now, and a simple map from your view on CRNX to the strategy that fits it. Model any of them in the calculator before you trade.
About CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) is a major company in Biotechnology. Options traders on CRNX tend to watch , since these can drive large moves in the share price.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals is a clinical-stage drug developer focused on treating rare endocrine disorders and hormone-related tumors. The company's most advanced candidate is Paltusotine, an oral medication designed to activate somatostatin receptor type 2, currently undergoing Phase 3 testing for acromegaly and carcinoid syndrome. Beyond its lead program, Crinetics is building a pipeline spanning multiple areas of endocrine disease. This includes Atumelnant, which blocks ACTH receptor signaling for conditions like Cushing's disease and congenital adrenal hyperplasia, along with programs targeting PTH receptor pathology, thyroid-stimulating hormone receptors, and newer initiatives in obesity treatment with oral GLP-1 and GIP candidates. The company also has a drug-conjugate candidate called CRN09682 aimed at somatostatin-receptor-positive solid tumors.
The company generates revenue primarily through licensing and partnership arrangements rather than product sales, given its clinical-stage status. It has licensed Paltusotine rights in Japan to Sanwa Kagaku Kenkyusho and granted development and commercialization rights for another somatostatin receptor agonist to Cellular…
Today's top-scoring strategy for CRNX
Our engine ranks defined-risk strategies on the live CRNX chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $70 | $0.11 |
| Sell | 1× | PUT | $77.5 | $0.83 |
| Sell | 1× | CALL | $92.5 | $0.82 |
| Buy | 1× | CALL | $100 | $0.11 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $106 | −$532 | −$499 | −$469 | −$443 | −$421 |
| $102 | −$430 | −$398 | −$374 | −$356 | −$343 |
| $97 | −$271 | −$261 | −$255 | −$253 | −$255 |
| $93 | −$93 | −$113 | −$132 | −$151 | −$171 |
| $89 | $41 | $2 | −$36 | −$73 | −$108 |
| $85 | $91 | $48 | $1 | −$44 | −$87 |
| $80 | $42 | $1 | −$40 | −$80 | −$117 |
| $76 | −$113 | −$136 | −$157 | −$178 | −$199 |
| $72 | −$336 | −$324 | −$317 | −$313 | −$313 |
| $68 | −$515 | −$488 | −$464 | −$445 | −$430 |
| $63 | −$591 | −$576 | −$557 | −$539 | −$522 |
Illustrative example at CRNX's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
CRNX is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on CRNX currently price in about 32% implied volatility, versus roughly 200% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$8.3 (±10%) in CRNX by 2026-09-18 — a range of roughly $76.36 to $92.96. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on CRNX trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
CRNX insider trading activity (SEC Form 4)
Open-market insider transactions at CRNX over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Vivaldi Coelho Rogerio | Sell | 3,000 | $120K | 2026-07-02 |
| Okey Stephanie | Sell | 608 | $22K | 2026-06-17 |
| Okey Stephanie | Sell | 6,292 | $224K | 2026-06-17 |
| Knight Jeff E. | Sell | 85,163 | $3.4M | 2026-04-08 |
| Knight Jeff E. | Sell | 3,961 | $150K | 2026-03-16 |
| Knight Jeff E. | Sell | 5,950 | $221K | 2026-03-16 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Key figures
- Market cap
- $8.9B
- Beta (vs market)
- 0.09
- 52-week range
- $25.83–$84.00 (100% up the range)
- Short interest
- 6.9% of float · 0.8 days to cover
How to choose an options strategy for CRNX
Start with your outlook on CRNX, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while CRNX stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open CRNX in the free calculator →
Frequently asked questions
What is the best options strategy for CRNX?
It depends on your outlook. Bullish traders often use a long call or bull call spread on CRNX; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are CRNX options liquid enough to trade?
Crinetics Pharmaceuticals, Inc. (CRNX) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade CRNX options?
Buying a single CRNX call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade CRNX or any security. Do your own research.
What does Crinetics Pharmaceuticals, Inc. do?
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the Biotechnology industry. The "About Crinetics Pharmaceuticals, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Crinetics Pharmaceuticals, Inc. pay a dividend?
We don't show a confirmed dividend yield for Crinetics Pharmaceuticals, Inc. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
Price trend
Tickers related to CRNX
Comparing CRNX with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 6055 Lusk Boulevard, San Diego, CA, 92121, United States
- Industry
- Biotechnology
- Employees
- 594
- CEO
- Dr. R. Scott Struthers Ph.D.
- Phone
- 858 450 6464
- Website
- www.crinetics.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.